Nyrada Inc
NYR
Company Profile
Business description
Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.
Contact
828 Pacific Highway
Suite 2, Level 3
GordonNSW2072
AUST: +61 294983390
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
Market Minute: RBA cuts rates again, US CPI data released
This week, the RBA cut rates after a surprise hold in July; CBA reported earnings ; US inflation data came out, showing its highest reading since February.
stocks
Is the market still overlooking Alibaba’s AI potential?
Despite a 40% share price rally this year, investors could still be underestimating Alibaba’s cloud growth prospects.
stocks
ASX reporting season wrap: CBA, JB Hi-Fi, REA and more
A round up of notable stories and reactions as ASX earnings season gathers steam.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,180.50 | 31.40 | 0.34% |
| CAC 40 | 7,870.34 | 65.37 | 0.84% |
| DAX 40 | 24,377.50 | 191.91 | 0.79% |
| Dow JONES (US) | 44,911.26 | 11.01 | -0.02% |
| FTSE 100 | 9,177.24 | 12.01 | 0.13% |
| HKSE | 25,183.70 | 335.62 | -1.32% |
| NASDAQ | 21,710.67 | 2.47 | -0.01% |
| Nikkei 225 | 43,036.46 | 387.20 | 0.91% |
| NZX 50 Index | 12,895.24 | 61.16 | 0.48% |
| S&P 500 | 6,468.54 | 1.96 | 0.03% |
| S&P/ASX 200 | 8,906.10 | 32.30 | 0.36% |
| SSE Composite Index | 3,674.97 | 8.52 | 0.23% |